<DOC>
	<DOCNO>NCT00006019</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one chemotherapy drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness phenylbutyrate plus azacitidine treating patient acute myeloid leukemia , myelodysplasia , non-Hodgkin 's lymphoma , multiple myeloma , non-small cell lung cancer , prostate cancer .</brief_summary>
	<brief_title>Phenylbutyrate Plus Azacitidine Treating Patients With Acute Myeloid Leukemia , Myelodysplasia , Non-Hodgkin 's Lymphoma , Multiple Myeloma , Non-small Cell Lung Cancer , Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine ability azacytidine vivo demethylate select gene know transcriptionally repressed patient acute myeloid leukemia , myelodysplasia , non-Hodgkin 's lymphoma , multiple myeloma , non-small cell lung cancer , prostate cancer . - Determine ability phenylbutyrate plus azacytidine induce transcription target gene know repressed consequence DNA methylation patient . - Determine effect treatment regimen upon gene methylation histone acetylation target cell patient . - Determine technical feasibility serially monitoring transcriptional activity methylation status select gene vivo patient . - Determine safety potential antitumor efficacy treatment regimen patient . OUTLINE : Patients receive azacytidine subcutaneously day 1-7 phenylbutyrate IV 1-2 hour day 8-12 . Patients acute myeloid leukemia respond therapy may receive second course approximately 10 day end first . Subsequent course patient , additional course patient , repeat every 21 28 day absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>4-phenylbutyric acid</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one follow neoplastic disease : Acute myeloid leukemia Myelodysplasia Low intermediate grade nonHodgkin 's lymphoma Multiple myeloma Nonsmall cell lung cancer Prostate cancer Failed prior conventional therapy know curative therapy exist Patients nonHodgkin 's lymphoma , nonsmall cell lung cancer , prostate cancer must tumor cell bone marrow malignant effusion accessible bone marrow aspiration paracentesis/thoracentesis NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Patients without leukemia myeloma : WBC least 2,500/mm^3 Platelet count least 75,000/mm^3 Hepatic : Bilirubin great 2.5 mg/dL Renal : Creatinine great 2.5 mg/dL Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 4 week study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Patients without leukemia : At least 3 week since prior cytotoxic chemotherapy Endocrine therapy : Not specify Radiotherapy : Patients without leukemia : At least 3 week since prior radiotherapy Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2002</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>